Moderna Inc. MRNA announced changes to its operating model and leadership structure. The biotechnology company is preparing ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

The company's pending vaccine approvals could help the stock continue its rise.

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50. Today they’ve nudged back to about $53 — but ...

Moderna received a unanimous advisory committee vote supporting mRNA-1010, its flu vaccine, for adults 50 and older. Read ...

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older ...

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed ...